NASDAQ:VOR

Vor Biopharma Stock Insider Trading

Healthcare > Biotechnology

Buy VOR

*Your capital is at risk

$14.85

-0.0900 (-0.602%)

At Close: Jun 23, 2026

Vor Biopharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -79.94. In total, the insiders bought 10.99M and sold 10.04M VOR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-79.94
● Buy	10.99M shares
● Sell	10.04M shares
20% Buy Activity Strong Negative Correlation
Sell Signal High Confidence Apr 13, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -79.94. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (20% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 11, 2026 Buy	Stock Option (Right to Buy) A-Award	Ra Capital Management, L.p.	Director	57 162 Value: $805.4K
Jun 11, 2026 Buy	Stock option (right to buy) A-Award	Detheux Michel Director	Director	57 162 Value: $805.4K
Jun 11, 2026 Buy	Stock Option (right to buy) A-Award	Namouni Fouad Director	Director	56 549 Value: $796.8K
Jun 11, 2026 Buy	Stock option (right to buy) A-Award	Joustra Wouter Director	Director	57 162 Value: $805.4K
Jun 11, 2026 Buy	Stock Option (right to buy) A-Award	Kalir Erez Director	Director	57 162 Value: $805.4K
Jun 11, 2026 Buy	Stock option (right to buy) A-Award	Cumbo Alexander Director	Director	56 345 Value: $793.9K
Jun 11, 2026 Buy	Stock option (right to buy) A-Award	Beckman Daniella Director	Director	53 283 Value: $750.8K
Jun 11, 2026 Buy	Stock option (right to buy) A-Award	Levin Andrew David Director	Director	57 162 Value: $805.4K
Apr 22, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	165 150 Value: $2.60M
Apr 20, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	171 963 Value: $2.71M
Apr 17, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	458 411 Value: $7.46M
Apr 15, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	53 644 Value: $858.8K
Apr 14, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	153 735 Value: $2.46M
Apr 13, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	530 610 Value: $8.57M
Apr 10, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	828 Value: $13.0K
Apr 09, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	135 201 Value: $2.24M
Apr 08, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	353 242 Value: $5.76M
Apr 08, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	130 862 Value: $2.21M
Apr 06, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	44 728 Value: $774.2K
Apr 06, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	6 775 Value: $125.3K
Apr 06, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	537 754 Value: $8.88M
Apr 02, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	1 525 Value: $29.1K
Apr 02, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	258 475 Value: $4.71M
Apr 01, 2026 Buy	Employee Stock Option (right to buy)	Sokolove Jeremy Brett Chief Medical Officer	Officer	130 100 Value: $1.06M
Apr 01, 2026 Buy	Common Stock	Sokolove Jeremy Brett Chief Medical Officer	Officer	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT VOR BIOPHARMA INC.

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, an...

Read Full Profile Here